---
title: "Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300613273.md"
description: "Monte Rosa Therapeutics will present Phase 1 GFORCE-1 data for MRT-8102 in subjects with elevated cardiovascular risk during an October 1 webcast. The update aims to disclose safety and activity findings across multiple dose levels after four weeks of treatment, highlighting evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease."
datetime: "2026-09-30T20:01:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300613273.md)
  - [en](https://longbridge.com/en/news/300613273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300613273.md)
generator: "portal-rs"
---

# Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects

-   Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects. \* Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment. \* The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301601PRIMZONEFULLFEED9837223) on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GLUE.US](https://longbridge.com/en/quote/GLUE.US.md)

## Related News & Research

- [GLUE: MRT-8102 normalized key ASCVD drivers and was well tolerated, supporting Phase 2 trials](https://longbridge.com/en/news/300675946.md)
- [MRT-8102 Delivers Broad Inflammation Reductions In Monte Rosa Trial](https://longbridge.com/en/news/300708514.md)
- [Xencor Reports 45.5% Confirmed Response Rate for XmAb819 at Selected Dose in Phase 1 Kidney Cancer Trial](https://longbridge.com/en/news/302982565.md)
- [AppLovin Corporation $APP Stock Purchased by Hedeker Wealth LLC](https://longbridge.com/en/news/303049441.md)
- [Marqeta (MQ) Expands With Square And Coinbase, Is The Stock Still Undervalued?](https://longbridge.com/en/news/302983307.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**